Beam Therapeutics' BEAM-302 Shows Durable AATD Treatment Effects in…

Event summary

Beam Therapeutics presented updated Phase 1/2 trial data for BEAM-302 at ERS Congress 2026, showing durable AATD treatment effects up to 18 months post-dosing.
Single-dose BEAM-302 increased total and functional AAT levels above protective thresholds in 29 patients, with 60 mg dose showing sustained efficacy.
BEAM-302 reduced mutant Z-AAT by 84% and decreased toxic Z-polymers, demonstrating potential to address both lung and liver manifestations of AATD.
Safety profile remained consistent with LNP-based therapies, with mild-to-moderate infusion-related reactions being the most common adverse events.
Global pivotal cohort dosing underway, targeting U.S. accelerated approval pathway based on 12-month biomarker endpoint.

The big picture

Beam Therapeutics' BEAM-302 represents a significant advancement in the treatment of alpha-1 antitrypsin deficiency (AATD), offering a potential genetic cure for both lung and liver manifestations. The durable efficacy and acceptable safety profile demonstrated in the Phase 1/2 trial position BEAM-302 as a potential first-in-class therapy, addressing a substantial unmet need in the AATD treatment landscape. The company's strategic focus on pursuing an accelerated approval pathway underscores its commitment to bringing this innovative therapy to patients as quickly as possible.

What we're watching

Regulatory Pathway: Whether the FDA will accept the proposed accelerated approval pathway based on biomarker endpoints.
Clinical Efficacy: The durability of BEAM-302's effects beyond the 18-month follow-up period in the ongoing pivotal cohort.
Competitive Positioning: How BEAM-302's potential as a one-time treatment compares to existing protein replacement therapies for AATD.